Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.
D., Will Retire After 15 Years at Company James Sabry, M.D.
, Ph.D., Appointed EVP, Chief Business Officer SAN RAFAEL, Calif.
, Aug. 21, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced the appointments of Greg Friberg , M.
D., as Executive Vice President, Chief Research & Development Officer, succeeding Hank Fuchs , M.D.
, and James Sabry , M.D., Ph.
D., as Executive Vice President, Chief Business Officer. Dr.
Friberg, who will join BioMarin effective Sept. 30 , is a proven leader with nearly two decades of industry experience. He comes to BioMarin from Amgen, Inc.
, where he most recently served as Vice President, Global Medical Affairs, Rare Disease. Dr. Friberg brings a wealth of experience in clinical development and lifecycle management to the role.
During his 18 years at Amgen, he has been responsible for advancing multiple medicines from investigational new drug application filing through late-stage development. In addition, he served as head of Global Development for the company's hematology/oncology and bone portfolios. At BioMarin, he will assume responsibility for the company's R&D organization, including discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs.
Dr. Friberg holds an M.D.
from New York Medical College . He completed his residency in internal medicine at Dartmouth-Hitchcock.